# Chaim Hurvitz

> Chaim Hurvitz is a Series A investor backing Health Care and Biotechnology. See 2 investments, round sizes, portfolio and contact details. Updated Nov 2026.

- Type: Angel Investor
- Location: Tel Aviv-yafo, Israel
- Total investments: 2
- Last investment: Aug 2018
- Lead investor: 0%
- Last updated: Nov 2026
- LinkedIn: https://www.linkedin.com/in/chaim-hurvitz-06a700365

Chaim Hurvitz is a Series A investor in Tel Aviv-yafo focused on Health Care and Biotechnology. Chaim Hurvitz is based out of Tel Aviv-yafo, Tel Aviv and is the CEO of CH Health. Chaim previously worked at Teva International Group as a President. Chaim Hurvitz attended the Tel Aviv University.

## Contacts

5 contacts available for Chaim Hurvitz: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/chaim-hurvitz?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 100% |
| Biotechnology | 2 | 100% |
| Pharmaceutical | 2 | 100% |
| Wellness | 1 | 50% |
| Biopharma | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 50% |
| Series D | 1 | 50% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| MyBiotics Pharma LTD | MyBiotics innovative technologies; MyCrobeTM and SuperDonorTM allow us to be in the front of the microbiome field. Both technologies resolve the three critical factors in the probiotic development market. Delivery, Targeting and Colonization. MyCrobeTM and SuperDonorTM provide single or multi-bacterial combinations for targeted treatment, wholemicrobiome restoration and the first actual screening method to replace FMT microbiome transplantations. MyBiotics focus is to return the bacterial population to its healthy and balanced state by using live bacteria that will colonize and compete with the existent disease-promoting population. | $8M | Series A | Aug 15, 2018 | https://mybiotics-pharma.com |
| PolyPid | PolyPid is a development stage company that has developed a platform technology for the healthcare industry that enables a controlled and prolonged release of any active pharmaceutical ingredients (API).PolyPid’s technology combines polymers and lipids, enabling small-and-large API entrapment in degradation and hydration protected environments,regardless of their chemical or physical characteristics.PolyPid allows the release of the API from the reservoir at pre-determined rates of up to several months, with a constant release rate (zero-order kinetics). The flexibility of this innovative technology enables local administration of compounds across numerous therapeutic classes for several applications. | $22M | Series D | Feb 23, 2016 | http://www.polypid.com |

2 of 2 investments shown.

## Co-investors
- AnGes — VC Fund, 1 deal together
- Aurum Ventures — VC Fund, 1 deal together
- [Shavit Capital](https://shizune.co/investors/profile/shavit-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [SOSV SF & NY (Fka IndieBio)](https://shizune.co/investors/profile/synbio-axlr8r) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [OurCrowd](https://shizune.co/investors/profile/ourcrowd) — VC Fund
- [Entrée Capital](https://shizune.co/investors/profile/entree-capital) — VC Fund
- [Pitango VC](https://shizune.co/investors/profile/pitango-venture-capital) — VC Fund

## Featured in investor lists
- [Biotechnology Angel Investors in Israel](https://shizune.co/investors/biotechnology-angel-investors-israel)
- [Biotech Angel Investors in Israel](https://shizune.co/investors/biotech-angel-investors-israel)

## FAQ

### What does Chaim Hurvitz invest in?

Chaim Hurvitz invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series A and Series D stage. Most of the 2 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Chaim Hurvitz?

Public channels for Chaim Hurvitz include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Chaim Hurvitz last invest?

The most recent investment recorded for Chaim Hurvitz closed in Aug 2018. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co
